Oncology Consortium

Impactful Education Through Innovative Engagement

roy.berger@theoncologyconsortium.com | (516) 729-0303

Biostatistics Oncology Consortium

Charles S. Davis, PhD

Bio-Statistics Oncology Consortium

Dr. Davis has provided biostatistical expertise in support of medical product development since 2005. Previously, he served as Vice President, Biometrics, at Elan Pharmaceuticals. Prior to joining Elan in 2001, he was Professor of Biostatistics at the University of Iowa. He is a Fellow of the American Statistical Association, author of the textbook Statistical Methods for the Analysis of Repeated Measurements (2002), and co-author of Categorical Data Analysis using the SAS System (1995). He has served as Chair of the ASA Biometrics Section (2000-2001), and as associate editor of Controlled Clinical Trials (1994-1998) and The American Statistician (2001-2005).

Gosford A. Sawyerr, MA

Bio-statistics Oncology Consortium

Gosford Sawyerr is currently an independent statistical consultant available to clients in the biopharmaceutical and medical device industry to assist with study design, statistical analysis and reporting, and to provide statistical counsel to interested persons and/or organizations. Gosford graduated with first class honors at the University of Ghana, Legon. After lecturing for two years at Legon, he embarked on graduate studies in statistics at the University of Rochester in update New York where he obtained his master’s in statistics.

Breast Oncology Consortium

Kimberly L. Blackwell, MD

Breast Oncology Consortium

Kimberly L. Blackwell is Professor of Medicine and Assistant Professor of Radiation Oncology at Duke University Medical Center. Since 2010, she has served as the director of the Breast Cancer Program in the Duke Cancer Institute, overseeing all basic and translational research programs involving breast cancer patients. Blackwell serves on the national Scientific Advisory Board of the Susan G. Komen Foundation.

Adam Brufsky, MD, PhD

Breast Oncology Consortium

Adam Brufsky, MD, PhD, is Professor of Medicine at the University of Pittsburgh Medical Center Health System and Director of the Magee Women’s Hospital/University of Pittsburgh Cancer Institute Comprehensive Breast Care Center. He is also Associate Chief of the Division of Hematology/Oncology. and Associate Director for Clinical Investigation for the University of Pittsburgh Cancer Institute.

Francisco J. Esteva, MD, PhD, FACP

Breast Oncology Consortium

Dr. Esteva is Professor of Medicine at New York University School of Medicine. He currently serves as Associate Director of Clinical Investigation, Director of Breast Medical Oncology and co-Director of the Breast Cancer Disease Management Group a the Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center.

William J. Gradishar, MD, FACP, FASCO

Breast Oncology Consortium

Dr. William J. Gradishar is the Betsy Bramsen Professor of Breast Oncology in the Division of Hematology and Medical Oncology, Department of Medicine, at the Feinberg School Medicine at Northwestern University in Chicago, Illinois, and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. He serves as Director of the Maggie Daley Center for Women’s Cancer Care. He has been Chair of the Annual Lynn Sage Breast Cancer Symposium since its inception 16 years ago. He served as Program Director of the Hematology Oncology Fellowship Training Program at Northwestern for 20 years. His research focuses on the development of novel therapeutics for the treatment of breast cancer.

Lee Schwartzberg, MD, FSCP

Breast and Supportive Care Oncology Consortium

Senior partner and Medical Director at The West Clinic, a 33 physician oncology, hematology and radiology practice in Memphis, TN. He did fellowship training in medical oncology and hematology at Memorial Sloan Kettering Cancer Center, where he also served as Chief Medical Resident and was a founding member of the institutional ethics committee. Dr. Schwartzberg is a Professor of Medicine and Division Chief of Hematology/Oncology at The University of Tennessee Health Science Center. He is President /CMO for ACORN Research, an oncology specific SMO/CRO.

Andrew D. Seidman, MD

Breast Oncology Consortium

Attending physician for the Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, and a Professor of Medicine, Joan and Sanford I. Weill Medical College of Cornell University. Dr. Seidman is the recipient of a Career Development Award from the American Society of Clinical Oncology (ASCO) for his research on the role of the taxanes in breast cancer treatment.

Sandra M. Swain, MD, FACP

Breast Oncology Consortium

Sandra M. Swain, MD, FACP is the Medical Director of the Washington Cancer Institute, of MedStar Washington Hospital Center, in Washington, DC. She is a Professor of Medicine at Georgetown University and Adjunct Professor of Medicine at Uniformed Services University of the Health Sciences. She was previously the Deputy Branch Chief of the Medicine Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH) and was a tenured Principal Investigator. She was also the Chief of the Breast Cancer Section, and Chief of the Cancer Therapeutics Branch.

Debu Tripathy, MD

Breast Oncology Consortium

Debu Tripathy, MD is Professor of Medicine and Chair, Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center. He received a degree in Chemical Engineering from the Massachusetts Institute of Technology and then completed medical school and an internal medicine residency at Duke University followed by a Hematology/Oncology fellowship at the University of California at San Francisco. He was formerly Professor of Clinical Medicine, Co-Leader of the Women’s Cancer Program and held the Priscilla and Art Ulene Chair in Women’s Cancer at the University of Southern California and USC/Norris Comprehensive Cancer Center.

Dermatologic Oncology Consortium

Ronald Bukowski, MD

Dermatologic and Urologic Oncology Consortium

Emeritus staff at the Cleveland Clinic Foundation, and Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University. He was recently the Deputy Director of the Cleveland Clinic Taussig Cancer Center and Director of the Experimental Therapeutics at the Cleveland Clinic Cancer Center. He held the James Zito Chair in Cancer Research at the Taussig Cancer Center from 2001 to 2008.

Marc S. Ernstoff, MD

Dermatologic Oncology Consortium

Dr. Ernstoff is Professor of Medicine, Geisel School of Medicine; and Staff Physician at the Lerner School of Medicine at the Cleveland Clinic. He is currently the Geisel PI on the Cancer Immunotherapy Trial Network and is on the executive council of the Cytokine Working Group. Dr. Ernstoff is also a member of the Alliance Experimental Therapeutics Program.

John M. Kirkwood, MD

Dermatologic Oncology Consortium

Director of the Melanoma and Skin Cancer Program at the University of Pittsburgh Cancer Institute and Professor and Vice Chairman for Clinical Research at the University of Pittsburgh School of Medicine. Dr. Kirkwood has received international acclaim for his research in biologic agents, cancer vaccines, and molecular changes in melanoma.

Mario E. Lacouture, MD

Dermatologic Oncology Consortium

Dr Lacouture is a Board-certified dermatologist with special interest in dermatologic conditions in people living with cancer. His clinical career has been focused on the recognition and management of side effects affecting the skin, hair, and nails of cancer patients and survivors. His clinical program provides pretreatment counseling and preventive efforts to minimize the development of adverse events as well as rapid attention to people who develop them. Close communication with treating oncologists ensures that interventions against untoward events do not affect the effectiveness of cancer treatments. In summary, the ultimate goal is to ensure the best dermatology-related quality of life and benefit from anticancer treatments.

Gastrointestinal Oncology Consortium

Tanios Bekaii-Saab, MD

Gastrointestinal Oncology Consortium

Tanios Bekaii-Saab, MD joined the faculty at The Ohio State University - Arthur G. James Cancer Hospital and Solove Research Institute in 2002 where he is a tenured Associate Professor of Medicine and Pharmacology and section chief for the gastrointestinal cancer program. He is also the chairman of the disease specific research group for the comprehensive cancer center. Dr. Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon, followed by residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana. He completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts.

Charles S. Fuchs, MD, MPH

Gastrointestinal Oncology Consortium

Charles S. Fuchs, MD, MPH, is Director of the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute, Professor of Medicine at Harvard Medical School and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer. He leads the Dana-Farber/Harvard Cancer Center Gastrointestinal Malignancies Program and the DF/HCC SPORE Grant in Gastrointestinal Cancers.

Axel Grothey, MD

Gastrointestinal Oncology Consortium

Axel Grothey, M.D., is a consultant in the Division of Medical Oncology, Department of Oncology, at Mayo Clinic. He holds the academic rank of professor of oncology and has teaching/examining privileges in Clinical & Translational Science at Mayo Graduate School. He is a member of Mayo Clinic’s Cancer Center.

Aiwa Ruth He, MD, PhD

Gastrointestinal Oncology Consortium

Dr. He is a GI Oncologist and Associate Professor at Lombardi Comprehensive Cancer Center, Georgetown University. The research focus of her laboratory is on the deregulation of signaling transduction pathways in carcinogenesis; and her expertise is in designing and implementing investigator initiated clinical studies.

Heinz-Josef Lenz, MD, FACP

Gastrointestinal Oncology Consortium

Dr. Lenz is Professor of Medicine and Professor of Preventive Medicine; Kathryn Balakrishnan Chair for Cancer Research; Associate Director, Clinical Research; Co-Chair of GI Oncology; and Co-Director USC Center for Molecular Pathways and Drug Discover at the University of Southern California Keck School of Medicine and USC/Norris Comprehensive Cancer.

John L. Marshall, MD

Gastrointestinal Oncology Consortium

Chief, Hematology and Oncology Lombardi Comprehensive Cancer Center Georgetown University. An internationally recognized expert in new drug development for GI cancer, with expertise in phase I, II, and III trial design, and has served as Principal Investigator for more than one hundred clinical trials. Established the Otto J Ruesch Center for the Cure of GI Cancers.

Michael Morse, MD, FACP

Gastrointestinal Oncology Consortium

Professor of Medicine in the Division of Medical Oncology at Duke University Medical Center, Durham, NC. Clinical expertise includes management of gastrointestinal malignancies and melanoma and his research expertise includes the development of targeted therapies including immunotherapies for cancer. He has published extensively and a national speaker on topics in cancer immunotherapy, targeted therapies, and gastrointestinal malignancies, including textbooks on Cancer Vaccines and Liver Tumors.

Weijing Sun, MD, FACP

Gastrointestinal Oncology Consortium

Weijing Sun, MD is Professor of Medicine, Director of GI Cancer of the Hematology-Oncology Division, and Co-Director of UPMC Gastrointestinal Cancer Center of Excellence at the University of Pittsburgh Cancer Institute. His focus is on the treatment and clinical research of GI malignances, mainly on the development of new drugs and biologic/targeted oriented agents in treatment/therapy (including translational research) of gastrointestinal malignances with great experience in the early phase clinical trials (phase I, II) by designing, developing and conducting clinical trials, many of which have been published.

Eugene A. Woltering, MD, FACS

Gastrointestinal Oncology Consortium

Eugene A. Woltering, MD, FACS, is the James D. Rives Professor of Surgery and Neurosciences at the Louisiana State University Health Sciences Center in New Orleans. He also is the Section Chief of Surgical Endocrinology and the Director of Surgical Research at this institution. Dr. Woltering attended medical school at Ohio State University School of Medicine and completed his surgical residency at Vanderbilt University Affiliated Hospitals in Nashville, Tennessee. He has also completed fellowships in surgical oncology at The Ohio State University School of Medicine and the National Cancer Institute. Dr. Woltering specializes in the diagnosis and management of neuroendocrine tumors of the gastro-entero-pancreatic tract. His research interests include the development of radioactive drugs for the diagnosis and therapy of tumors and the development of human tissue based models that can be used to predict drug activity in patients.

Geriatrics Oncology Consortium

Stuart M. Lichtman, MD, FACP

Geriatric and Gynecologic Oncology Consortium

Dr. Lichtman is an Attending Physician and Member, Memorial Sloan-Kettering Cancer Center and Professor of Medicine, Weill Cornell Medical College. He is a member of the 65+ Clinical Geriatrics Program and Gynecologic Oncology Disease Management Team at the Center. He coauthored the book, "Management of Gynecological Cancers in Older Women", and paper on gynecologic cancer in the special Geriatric Oncology edition of the Journal of Clinical Oncology.

Gynecologic Oncology Consortium

Thomas Herzog, MD

Gynecologic Oncology Consortium

Director of Gynecologic Oncology and the Physicians & Surgeons Endowed Professor of Clinical Gynecology and Obstetrics, Columbia University. Served as a Principal Investigator in a number of GOG trials with a special emphasis in ovarian and endometrial cancers. Dr. Herzog has authored or co-authored over 185 peer-reviewed articles and lectures extensively. He serves on the editorial boards of Gynecologic Oncology, Obstetrics and Gynecology International, Hematology Oncology Times, and others.

Stuart M. Lichtman, MD, FACP

Geriatric and Gynecologic Oncology Consortium

Dr. Lichtman is an Attending Physician and Member, Memorial Sloan-Kettering Cancer Center and Professor of Medicine, Weill Cornell Medical College. He is a member of the 65+ Clinical Geriatrics Program and Gynecologic Oncology Disease Management Team at the Center. He coauthored the book, "Management of Gynecological Cancers in Older Women", and paper on gynecologic cancer in the special Geriatric Oncology edition of the Journal of Clinical Oncology.

William P. McGuire, MD

Gynecologic Oncology Consortium

Medical Director of The Harry and Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center in Baltimore, MD. Clinical Professor of Medicine and Oncology at Georgetown University’s Lombardi Comprehensive Cancer Center. Dr. McGuire’s research interests include gynecologic oncology, experimental therapeutics, and cancer management. Dr. McGuire is actively involved in a number of professional societies, including the Gynecologic Oncology Group, the American College of Obstetricians and Gynecologists.

Head and Neck Oncology Consortium

Julie Bauman, MD

Head and Neck Oncology Consortium

Dr. Julie Bauman is an Associate Professor of Medicine (Division of Hematology/Oncology) at the University of Pittsburgh Cancer Institute (UPCI), an NCI-designated Comprehensive Cancer Center. She was recruited in 2012 to serve as the Section Chief of Head and Neck Cancer (HNC), and Co-Leader of the UPMC HNC Center of Excellence. Dr. Baumann’s major goal is to design rigorous, biomarker-driven clinical trials to improve survival and survivorship in Head and Neck cancers.

Ezra Cohen, MD

Head and Neck Oncology Consortium

Ezra Cohen, MD is Professor of Medicine, UC San Diego Moores Cancer Center and Associate Director for Translational Science and team leader in Head and Neck Oncology as well as the Solid Tumor Therapeutics research program. He is an internationally renowned translational researcher, who has been acknowledged for his contribution to the National Cancer Institute Task Force on PI3 Kinase/AKT/mTOR Targeting. Among other roles, he chairs the Protocol Review and Monitoring Committee (PRMC) and serves as a member of the Cancer Council, C3 steering committee, and the cancer center’s Executive Committee. He was recently appointed as chair of the NCI Head and Neck Cancer Steering Committee that oversees NCI-funded clinical research (including all NCI Cooperative Group trials) in this disease.

Alan Ho, MD, PhD

Head and Neck Oncology Consortium

Alan L. Ho MD, PhD is a medical oncologist on the solid tumor service at Memorial Sloan Kettering Cancer Center. He did his undergraduate work at Washington University School of Medicine and Medical School at Stanford University, where he graduated Phi Beta Kappa. He did his Residency at Weill Cornell-NY Presbyterian and Fellowship at MSKCC. He specializes in the management of head and neck squamous cell carcinomas, thyroid cancers, salivary cancers, and non-melanoma skin cancers. His research is focused upon the translational science of developing novel therapeutics for these malignancies. He is the principal investigator (PI) of two NIH R01s and a co-PI in the MSK Thyroid Cancer Spore program. He is a member of the Experimental Therapeutics Committee in the Alliance for Clinical Trials in Oncology, and has served as the national PI of an NCI-cooperative group trial. Dr. Ho is currently the National Translational PI of the NCI MATCH clinical trial effort evaluating a hedgehog pathway inhibitor. He serves as a co-chair of the head and neck subsection of the International Clinical Trials in Rare Cancers Initiative and is a member of the National Comprehensive Cancer Network (NCCN) practice guidelines committee for the management of non-melanoma skin cancers. He is also the current chair of the MSK Investigational New Drug committee.

Lori Wirth, MD

Head and Neck Oncology Consortium

Dr. Wirth is the Medical Director of the Center for Head and Neck Cancer as Massachusetts General Hospital in Boston, and Assistant Professor at Harvard Medical School. She is the Secretary and Protocol Chair of the International Thyroid Oncology Group (ITOG), and will assume the Chairmanship of ITOG in May, 2015. Dr. Wirth is on NCCN’s Thyroid Cancer Committee and the NCI’s Head and Neck Cancer Recurrent/Metastatic Disease Task Force. Dr. Wirth’s research focuses on advanced thyroid cancer and clinical trials in squamous cell carcinoma of the head and neck.

Leukemia, Lymphoma, And Myeloma Oncology Consortium

James O. Armitage, MD

Leukemia, Lymphoma, And Myeloma Oncology Consortium

Dr. James O. Armitage, a graduate of the University of Nebraska Medical Center, completed his internship and residency in Internal Medicine at Nebraska, a fellowship in Hematology/Oncology at the University of Iowa and a brief stint in private practice in Omaha. He developed and directed the Bone Marrow Transplant program at the University of Iowa and later at the University of Nebraska. At Nebraska he served as Vice-Chair of Internal Medicine, Chief of the Section of Oncology and Hematology, Chair of the Department of Internal Medicine, and Dean of the College of Medicine. He currently is The Joe Shapiro Professor of Medicine at the University of Nebraska Medical Center. Dr. Armitage is board certified in Internal Medicine, Medical Oncology, and Hematology, and a Fellow of both the American and Royal College of Physicians and of the American Association for the Advancement of Sciences. He has served on many national/international oncology committees including the United States National Cancer Advisory Board and the French National Cancer Advisory Board. He is past president of both the American Society of Clinical Oncology and the American Society of Blood and Marrow Transplantation. He has served on the Scientific Committee of the International Congress on Anti-Cancer Treatment in Paris, France, the International Symposium on Hodgkin Lymphoma in Cologne, Germany and the International Conference on Malignant Lymphoma in Lugano, Switzerland.

Sergio A. Giralt, MD

Leukemia, Lymphoma, and Myeloma Oncology Consortium

Sergio A. Giralt, MD is the Chief of the Adult Bone Marrow Transplant Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center in New York, New York. He is affiliated with Weill Cornell Medical College as a Professor of Medicine. He received his medical degree from Universidad Central de Venezuela in Caracas, Venezuela, and completed his postgraduate internship at the University Hospital of Caracas. He also completed an internal medicine residency at Good Samaritan Hospital in Cincinnati, Ohio and a postdoctoral fellowship in hematology and oncology at The University of Texas MD Anderson Cancer Center.

Andre Goy, MD

Leukemia, Lymphoma, And Myeloma Consortium

Andre Goy, MD is the Chairman and Director of the John Theurer Cancer Center at Hackensack University Medical Center, as well as the Lymphoma Division Chief. He is the Chief Science Officer and Director of Research and Innovation of Regional Cancer Care Associates. Dr. Goy also holds the title of Professor of Medicine, Georgetown University. Dr Goy, completed his medical training in France then joined Sloan Kettering Institute for a post-doc in molecular oncology before his appointment at Weill Cornell Medical College and joining Memorial Sloan Kettering Cancer Center as attending in the Lymphoma Service. Dr. Goy then joined MD Anderson Cancer Center in Houston as faculty on the Lymphoma Service and as assistant professor at the University of Texas. He was appointed at John Theurer Cancer Center in 2005 as Chief of Lymphoma before becoming Deputy Director and now Chairman and Executive Director of the cancer center. He has published more than 100 articles and serves as reviewer for a number of journals including Journal of Clinical Oncology, Blood, Cancer and Clinical Cancer Research among others. Dr Goy is also the Editor-in-Chief of Oncology & Biotech News.

Steven Horwitz, MD

Leukemia, Lymphoma, and Myeloma Oncology Consortium

Dr. Steven Horwitz is a medical oncologist who serves as an Assistant Professor at both the Joan and Sanford I. Weill Medical College Department of Medicine, Cornell University, New York Presbyterian Hospital and Memorial Sloan-Kettering Cancer Center, New York, NY. His focus is on the care of patients with lymphoma, with a research sub-specialty interest in the development of new therapies for T-cell and cutaneous lymphomas as well as lymphoproliferative disorders developing in immunosuppressed patients after organ transplant.

Sundar Jagannath, MD

Leukemia, Lymphoma, and Myeloma Oncology Consortium

Dr. Jagannath is Director of the Multiple Myeloma Program at Mount Sinai Hospital’s Tisch Cancer Institute and Professor of Medicine at Icahn School of Medicine, N.Y., N.Y. A board-certified internal medicine and medical oncology specialist, he received his medical degree, Maharaja Sayajirao University, Baroda, India. He completed an immune-virology fellowship at McMaster UMC, Ontario, Canada. His residency was completed at the Bronx-Lebanon Hospital in Bronx, N.Y. and at Harper-Grace Hospital, Wayne State University, Detroit, MI. He completed a medical oncology fellowship at University of Texas System Cancer Center–M.D. Anderson Hospital and Tumor Institute, Houston, TX. He was Professor of Pathology and Medicine, University of Arkansas, where he served as Bone Marrow Transplantation Chief. He was the Bone Marrow Transplant and Multiple Myeloma Program Chief at St. Vincent’s CCC, N.Y., N.Y.

Charles A. Schiffer, MD, PhD

Leukemia, Lymphoma, and Myeloma Oncology Consortium

Charles A. Schiffer, MD, is Professor of Medicine and Oncology at Wayne State University School of Medicine and the Karmanos Cancer Institute in Detroit, Michigan. He is the director of the Leukemia/Lymphoma Multidisciplinary Program. Dr. Schiffer earned his BA cum laude at Brandeis University and his M.D. at New York University School of Medicine. He completed his internship, residency, and chief residency in Internal Medicine at Bellevue Hospital under the auspices of New York University School of Medicine and had subsequent training and positions at the Baltimore Cancer Research Institute, National Cancer Institute and the University of Maryland School of Medicine, where he served as Chief of the Division of Hematology. He has also served as Chief of the Division of Hematology/Oncology and Director of Clinical Research at the Karmanos Cancer Institute.

Richard Stone, MD

Leukemia, Lymphoma, and Myeloma Oncology Consortium

Richard Stone, MD, is the Chief of Staff and Director of the Adult Acute Leukemia Program at Dana-Farber, and Professor of Medicine at Harvard Medical School. Dr. Stone is nationally recognized for his translational and clinical research concerning blood and bone marrow malignancies including acute leukemia, myeloproliferative disorders and myelodysplastic syndrome [MDS] (a bone marrow failure state that may convert to leukemia).

Martin S. Tallman, MD

Leukemia, Lymphoma, and Myeloma Oncology Consortium

Martin S. Tallman, M.D. is Chief, Leukemia Service at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College in New York, USA. Previously, he was Professor of Medicine at the Northwestern University Feinberg School of Medicine, USA and Co-Director of the Hematologic Malignancy Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago, Illinois, USA. He is a diplomate of the American Board of Internal Medicine with sub-specialty certification in the areas of hematology and medical oncology. He serves as Chair of the Leukemia Committee of the Eastern Cooperative Oncology Group.

Andrew D. Zelenetz, MD

Leukemia, Lymphoma, and Myeloma Oncology Consortium

Andrew D. Zelenetz, MD, PhD is the Vice Chair, Medical Informatics in the Department of Medicine at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York. Prior to that, he was Chief, Lymphoma Service in the Division of Hematology/Oncology at MSKCC. He is also Associate Professor of Medicine at Weill Medical College of Cornell University. Dr Zelenetz’s research focuses primarily on improving clinical outcomes in lymphoma and on the molecular mechanisms of non-Hodgkin lymphoma. Throughout his career, his research has been published in such journals as BLOOD, the Journal of Clinical Oncology and Clinical Cancer Research. He received his BA, PhD, and MD from Harvard University. Both his internship and residency were completed at Stanford University as well as a clinical and research fellowship in oncology.

Neuro-Oncology Consortium

Henry S. Friedman, MD

Neuro-Oncology Consortium

Dr. Henry S. Friedman is an internationally renowned academic adult and pediatric neuro-oncologist who helps to lead The Preston Robert Tisch Brain Tumor Center at Duke University. He is the author of more than 500 peer reviewed articles, reviews, and book chapters and has presented extensively at both international and national meetings.

Adam Mamelak, MD

Neuro-Oncology Consortium

Dr. Adam Mamelak is Professor of Neurosurgery and Co-director of the Pituitary Center at Cedars-Sinai Medical Center in Los Angeles. His primary interests encompass pituitary and skull base surgery, epilepsy and brain tumors.

Michael D. Prados, MD

Neuro-Oncology Consortium

Michael Prados was a Fellow in Neuro-Oncology at the University of California San Francisco in 1985. Following a two year training program, he was recruited to the Faculty in 1988 and has remained at UCSF since that time, and is now Professor-in-Residence and the Charles B Wilson Chair of Neurosurgery. His career interests center around patient care, and clinical and translational research. He became the Project Leader of the North America Brain Tumor Consortium (NABTC) and led that group for 15 years. When the NABTC merged with the NABTT (and became the Adult Brain Tumor Consortium) he was named co-Project Leader. In 2009, he was awarded the Project Leadership of the Ivy Foundation Early Phase Clinical Trials Consortium, a group of now 7 major academic centers who conduct clinical and translation research in adults with brain cancer.

John H. Sampson, MD, PhD, MBA, MHSc

Neuro-Oncology Consortium

Dr. Sampson is a Chief of Neurosurgery at Duke University with doctoral level training in Immunology and an MBA from a top Business School whose research interest is in brain tumor drug delivery and immunotherapy -- activating a patient’s immune system to recognize and kill tumors. His research examines the ability of immune cells to specifically target tumor cells with little to no normal cell toxicity. He has already developed two vaccines targeting tumor-specific antigens that promises to extend the lifespan of patients with brain tumors in prospective, randomized, and placebo-controlled trials. He is currently the PI of several international trials for immunotherapy in brain tumors based on his own work and work from global pharmaceutical companies.

Oncology Nursing Consortium

Denise Albano, RN, NP

Oncology Nursing Consortium

Denise Albano, RN, NP, graduated from Stony Brook University as a nurse practitioner with a master’s degree in science in 1998. She is presently in the doctorate program at Stony Brook University and has been practicing as an adult oncology nurse practitioner in a full time roll since graduation. She earned her NP certification from the Academy of Nurse Practitioners.

Amy Goodrich, RN, MSN, CRNP, RA

Oncology Nursing Consortium

Amy Goodrich, RN, MSN, CRNP, Research Associate, is a Nurse Practitioner in the Hematologic Malignancies Program and Research Nursing Manager at The Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland. Ms. Goodrich manages patients with various types of hematologic malignancies, concentrating on the lymphomas. She also manages the Cancer Center’s research nurses and is extremely involved in research operations.

Judith K. Payne, PhD, RN, AOCN, FAAN

Oncology Nursing Consortium

Dr. Judith Payne is past Director of Nursing Research and Evidence-Practice, University of Wisconsin Hospital and Clinics, Madison, Wisconsin. She has expertise and experience in oncology administration, research, and clinical practice, and has received several awards in these areas including the Young Research Award from Duke University Comprehensive Center and the ONS State-of-the-Science Lectureship Award from the Oncology Nursing Society. She is a fellow in the American Academy of Nursing and currently serves as the Co-Chair of the Academy’s Health Behavior Expert Panel. Dr Payne is active in ONS and speaks nationally on a variety of nursing issues.

Julie Ann Plantamura, RN, MSN, FNPc

Oncology Nursing Consortium

Julie Ann Plantamura, RN, MSN, FNPc, is a Board-certified Nurse Practitioner with North Shore Hematology-Oncology Associates, P.C. (NSHOA) in East Setauket, New York. At NSHOA, which she joined in 2001, she provides direct care and treatment to hematology and oncology patients as well as serving patients who are participating in many clinical trials. She lectures extensively on many aspects of oncology care throughout the US.

Kathleen M. Shurpin, PhD, ANP-C, NPP, RN

Oncology Nursing Consortium

Dr. Shurpin obtained her undergraduate and graduate degrees in nursing from Adelphi University, Garden City N.Y. She holds certifications as a Registered Professional Nurse, an Adult Nurse Practitioner, and a Psychiatric-Mental Health Nurse Practitioner. She currently holds the position of Professor in the Stony Brook University School of Nursing. In addition to her professorship, Dr. Shurpin currently serves as the director of the Doctorate in Nursing Practice (DNP) Program. She is also engaged in support groups for cancer patients and families. Dr. Shurpin has been director of both the Adult Health Nurse Practitioner Program and the Family Nurse Practitioner Program. She has also directed the undergraduate nursing program. Her research interests include oncology and educational technologies. She serves on many national and regional committees related to nursing education and practice.

Sylvia K. Wood, DNP, APRN, ANP-BC

Oncology Nursing Consortium

Sylvia K. Wood is an adult Nurse Practitioner, with over 35 yrs of nursing experience. She has practiced in oncology for the last 25 yrs with emphasis in hematologic malignancies, bone marrow transplant, breast cancer and palliative care. Dr Wood has been involved in clinical trial research in areas of bone marrow transplant, hematologic malignancies and solid tumors with interest in evidence-based research to improve clinical practice outcomes. She has works with the Oncology Nursing Society in a program called “Putting Evidence Into Practice” in order to support oncology nursing education and clinical practice. Dr. Wood received her Bachelor of Science degree in Nursing at Roberts Wesleyan College in Rochester, New York and she received her Master of Science in the Adult Nurse Practitioner program and her Doctorate of Nursing Practice at Stony Brook University. Currently Dr. Wood serves on the full-time faculty in the Department of Nursing at St Joseph’s College. She has lectured extensively and is the lead author for articles on treatment-related side effects of cancer published in peer-reviewed journals.

Pediatric Oncology Consortium

John M. Goldberg, MD

Pediatric Oncology Consortium

John M. Goldberg, is an Assistant Professor of Clinical Pediatrics and Director of the Pediatric Oncology Early Phase Clinical Trials Program at the University of Miami Sylvester Comprehensive Cancer. His research focuses on the translation of laboratory discoveries into new therapies for patients. Dr. Goldberg’s particular interests include immunotherapy, new treatments for leukemia, lymphoma, sarcoma, brain tumors,and the development of HDAC inhibitors for children with cancer. He trained at the Dana-Farber Cancer Institute in the laboratory of David E. Fisher, where he developed a background in molecular oncology, and carried out immunotherapy and targeted trials with the adult melanoma and sarcoma groups.

Robert G. Maki, MD, PhD, FACP

Pediatric Oncology and Sarcoma Consortium

Robert Maki is Professor in the Departments of Medicine and Orthopaedics, and also Section Chief in Pediatric Hematology-Oncology at Tisch Cancer Institute, Mt Sinai Medical Center in New York. He trained at Dana Farber Cancer Center and worked there as well as becoming Section Chief of the Adult Sarcoma Division at MSKCC with an Appointment as Associate Professor at Cornell University, Weill Medical College.

Sarcoma Consortium

Robert G. Maki, MD, PhD, FACP

Pediatric Oncology and Sarcoma Consortium

Robert Maki is Professor in the Departments of Medicine and Orthopaedics, and also Section Chief in Pediatric Hematology-Oncology at Tisch Cancer Institute, Mt Sinai Medical Center in New York. He trained at Dana Farber Cancer Center and worked there as well as becoming Section Chief of the Adult Sarcoma Division at MSKCC with an Appointment as Associate Professor at Cornell University, Weill Medical College.

Richard F. Riedel, MD

Sarcoma Consortium

Dr. Riedel is an Associate Professor in the Division of Medical Oncology at Duke University Medical Center and Associate Director for Clinical and Translational Research for the Duke Sarcoma Program, within the Duke Cancer Institute.

Scott Schuetze, MD, PhD

Sarcoma Consortium

Dr. Scott Schuetze is a Clinical Professor, Department of Internal Medicine. He received his MD and PhD from Oregon Health Sciences University in 1993. Dr. Schuetze completed his residency at Duke University Medical Center in 1996. His Oncology Fellowship followed at Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA.

Jonathan C. Trent, MD, PhD

Sarcoma Consortium

Dr. Jonathan C. Trent earned his undergraduate degree in chemistry at Southeastern Oklahoma State University and his MD and PhD in cancer biology from The University of Texas Health Science Center. He completed an internship and residency in internal medicine at The University of Texas Health Science Center, and a fellowship in medical oncology at The University of Texas M. D. Anderson Cancer Center while serving as chief fellow. Prior to joining the University of Miami, Miller School of Medicine, he held appointments as faculty of the University of Texas Graduate School of Biomedical Sciences at Houston, and Associate Professor of Medicine in the Department of Sarcoma Medical Oncology, Division of Cancer Medicine at the University of Texas M.D. Anderson Cancer Center in Houston. Dr. Trent is currently the Associate Director for Clinical Research for the Sylvester Comprehensive Cancer Center, the Co-Director of the Musculoskeletal Center, and the Director for Bone and Soft-tissue Sarcoma.

Supportive Care Oncology Consortium

David H. Henry, MD

Supportive Care Oncology Consortium

Dr. David Henry completed his Medical Oncology/Hematology fellowship at the Hospital of University of Pennsylvania in Philadelphia. After two years in the Air Force at Wilford Hall Medical Center, San Antonio, Texas in Oncology, he returned to Philadelphia in Clinical Practice at the Graduate Hospital and now is entirely at the Pennsylvania Hospital, part of the Abramson Cancer Center of the University of Pennsylvania. He is Clinical Professor of Medicine and Vice Chairman of Department of Medicine at Pennsylvania Hospital.

Lee Schwartzberg, MD, FSCP

Breast and Supportive Care Oncology Consortium

Senior partner and Medical Director at The West Clinic, a 33 physician oncology, hematology and radiology practice in Memphis, TN. He did fellowship training in medical oncology and hematology at Memorial Sloan Kettering Cancer Center, where he also served as Chief Medical Resident and was a founding member of the institutional ethics committee. Dr. Schwartzberg is a Professor of Medicine and Division Chief of Hematology/Oncology at The University of Tennessee Health Science Center. He is President /CMO for ACORN Research, an oncology specific SMO/CRO.

Winston W. Tan, MD

Supportive Care and Urologic Oncology Consortium

Dr. Winston Tan has been engaged in research with a focus on genitourinary cancer, including prostate cancer, since 1997. His research has focused on two distinct areas: developing novel therapeutic agents for patients with genitourinary cancer, and developing interventions/ recognizing quality of life issues in patients with genitourinary cancer. He specifically is interested and has published on issues regarding bone health. He has written and completed several investigator-initiated Phase II clinical trials, served as a principal investigator on multiple trials, and additionally has served as a principal investigator for a Phase III clinical trial. He has authored 31 peer reviewed articles, seven book chapters and 45 abstracts.in addition,Dr. Tan actively runs the medical oncology clinic for kidney cancer at the Mayo Clinic in Jacksonville, Florida. He is an active member of Genitourinary Committee with the Eastern Cooperative Oncology Group.

Thoracic Oncology Consortium

Paul A. Bunn, Jr., MD

Thoracic Oncology Consortium

Dr. Bunn’s studies have set standards for the treatment of lung cancer, have identified issues of natural history and have identified biomarkers of prognosis and therapy selection. Dr. Bunn is the principal investigator on numerous national and local therapeutic trials and is also the principal investigator for the SPORE grant in lung cancer that is designed to conduct lung cancer translational research and Principal Investigator for the Lung Cancer Mutation Consortium.

David Gandara, M.D.

Thoracic Oncology Consortium

David R. Gandara, MD, Professor of Medicine at the University of California at Davis (UC Davis) School of Medicine, is the Senior Advisor to the Director, and Director of the Thoracic Oncology Program at UC Davis Comprehensive Cancer Center. He is a diplomat of the American Board of Internal Medicine specializing in Medical Oncology.

Primo Lara, MD

Thoracic and Urologic Oncology Consortium

Dr. Lara is Professor of Medicine at the University of California Davis School of Medicine. He is also Associate Director for Translational Research and Co-Leader of the Cancer Therapeutics Program at the UC Davis Comprehensive Cancer Center, a National Cancer Institute-designated cancer center. His principal research interest is in the field of developmental therapeutics, particularly in thoracic and genitourinary malignancies.

Joan Schiller, M.D.

Thoracic Oncology Consortium

Dr. Joan Schiller is widely published and internationally recognized for her work in lung cancer clinical research. She is the Deputy Director of Simmons Comprehensive Cancer Center, holds the Andrea L. Simmons Distinguished Chair in Cancer Research, and is division director of Hematology/Oncology at the University of Texas-Southwestern Medical Center in Dallas, which ranks among the top academic medical centers in the world. Dr. Schiller is also the principal investigator on many Phase I, II and III investigator-initiated and national clinical trials for lung cancer. For ten years, she served as chairperson of the Thoracic Oncology Committee of the Eastern Co-operative Oncology Group.

Urologic Oncology Consortium

E. Roy Berger, MD, FACP

Urologic Oncology Consortium

Assistant Clinical Professor of Medicine, SUNY Stony Brook College of Medicine Stony Brook, NY. Medical Oncologist with over 30 years of experience in the diagnosis and treatment of solid tumors, hematologic malignancies and supportive care. Founding member of the Prostate Cancer Education Council, a group that sponsors free prostate cancer screenings nationally. In addition, he serves on the medical advisory boards of two of the largest patient advocacy groups in the US for patients with prostate cancer. Authored over 50 peer reviewed articles and participated in 100 clinical trials.

Ronald Bukowski, MD

Dermatologic and Urologic Oncology Consortium

Emeritus staff at the Cleveland Clinic Foundation, and Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University. He was recently the Deputy Director of the Cleveland Clinic Taussig Cancer Center and Director of the Experimental Therapeutics at the Cleveland Clinic Cancer Center. He held the James Zito Chair in Cancer Research at the Taussig Cancer Center from 2001 to 2008.

Sia Daneshmand, MD

Urologic Oncology Consortium

Dr. Sia Daneshmand has been selected as one of “True Experts” in the Testicular Cancer Resource Center web site, and serves on the scientific advisory board of the bladder cancer advocacy network (BCAN). He has been elected to the Alpha Omega Alpha medical honor society, and has been designated one of the “America’s Top Cancer Doctors” and “America’s Top Urologists” and “America’s Top Doctors” for the past 6 years. He is an active member of the Society of Urologic Oncology, has presented over 200 abstracts at scientific meetings and authored over 180 peer-reviewed articles, reviews, and chapters.

Stephen Freedland, MD

Urologic Oncology Consortium

Dr. Stephen Freedland is a Professor of Surgery (Urology) at Cedars-Sinai Medical Center in Los Angeles, CA. He is Associate Director of the Samuel Oschin Comprehensive Cancer Institute and Director of the Center for Integrated Research on Cancer and Lifestyle. Until the end of 2014, he was an Associate Professor of Surgery (Urology) and Pathology at Duke University. He is Editor-in-Chief of Prostate Cancer and Prostatic Diseases and sits on the editorial board of numerous international journals in Urology and Cancer. He specializes in the diagnosis, treatment, and long-term management of prostate cancer patients. He has extensive research interests in risk stratification, the role of obesity and nutrition in prostate cancer, and health disparities for prostate cancer. He completed his undergraduate at UCLA and then medical school at UC Davis. Following this, he completed his residency in Urology at UCLA and a urological oncology fellowship at Johns Hopkins. He currently runs an active research program with funding from the National Cancer Institute and the Department of Defense.

Thomas E. Hutson, DO

Urologic Oncology Consortium

Director of the Genitourinary Oncology Program and Co-Director of the Center of Excellence for Texas Oncology in the Charles A. Sammons Cancer Center at Baylor University Medical Center; and Co-Chair of Genitourinary Research for US Oncology. Professor of Medicine at Texas A&M Health Science Center College of Medicine.

Primo Lara, MD

Thoracic and Urologic Oncology Consortium

Dr. Lara is Professor of Medicine at the University of California Davis School of Medicine. He is also Associate Director for Translational Research and Co-Leader of the Cancer Therapeutics Program at the UC Davis Comprehensive Cancer Center, a National Cancer Institute-designated cancer center. His principal research interest is in the field of developmental therapeutics, particularly in thoracic and genitourinary malignancies.

Robert Motzer, MD

Urologic Oncology Consortium

Dr. Motzer serves as Attending Physician, Division of Solid Tumor Oncology, Department of Medicine, Memorial Hospital for Cancer and Allied Disease as well as Attending Physician and Professor of Medicine, Weill Medical College of Cornell University and New York Presbyterian Hospital.

Brian I. Rini, MD, FACP

Urologic Oncology Consortium

Brian I. Rini, MD, FACP is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio. A Staff member of the Department of Solid Tumor Oncology and Co-Leader of the Genitourinary Program of the CASE Comprehensive Cancer Center, Dr. Rini’s work focuses on genitourinary malignancies. Dr. Rini earned his medical degree at the Ohio State University College of Medicine. He completed a Residency program in Internal Medicine and a Fellowship in Hematology / Oncology at University of Chicago Hospitals. Dr. Rini was an Assistant Professor at the University of California San Francisco before moving to The Cleveland Clinic.

Charles J. Ryan, MD

Urologic Oncology Consortium

Charles J Ryan, MD, is a Professor of Medicine and Urology at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF). He is the Leader of the Genitourinary Medical Oncology Program, overseeing the clinical research efforts of a group of nine genitourinary medical oncologists conducting clinical trials in prostate, kidney and bladder cancer.

Mark C. Scholz, MD

Urologic Oncology Consortium

A board-certified medical oncologist, Mark C. Scholz, MD, serves as medical director of Prostate Oncology Specialists Inc. in Marina del Rey, CA, a medical practice exclusively focused on prostate cancer. He is also the executive director of the Prostate Cancer Research Institute. He received his medical degree from Creighton University in Omaha, NE, Dr. Scholz completed his Internal Medicine internship and Medical Oncology fellowship at University of Southern California Medical Center.

Cora N. Sternberg, MD, FACP

Urologic Oncology Consortium

Dr. Sternberg was the Coordinator for Genitourinary Oncology Education for the European Society for Medical Oncology (ESMO) for many years and has also served on the nominating Committee. She has served as the Genitourinary Oncology Program Chairman for the European CanCer Organisation (ECCO) and coordinated the first European Multidisciplinary Genitourinary Cancer Symposium (EMUC).

Winston W. Tan, MD

Supportive Care and Urologic Oncology Consortium

Dr. Winston Tan has been engaged in research with a focus on genitourinary cancer, including prostate cancer, since 1997. His research has focused on two distinct areas: developing novel therapeutic agents for patients with genitourinary cancer, and developing interventions/ recognizing quality of life issues in patients with genitourinary cancer. He specifically is interested and has published on issues regarding bone health. He has written and completed several investigator-initiated Phase II clinical trials, served as a principal investigator on multiple trials, and additionally has served as a principal investigator for a Phase III clinical trial. He has authored 31 peer reviewed articles, seven book chapters and 45 abstracts.in addition,Dr. Tan actively runs the medical oncology clinic for kidney cancer at the Mayo Clinic in Jacksonville, Florida. He is an active member of Genitourinary Committee with the Eastern Cooperative Oncology Group.

Nicholas Vogelzang, MD

Urologic Oncology Consortium

Dr. Vogelzang is Clinical Professor of Medicine at the University of Nevada School of Medicine, and a Medical Oncologist at the Comprehensive Cancer Centers of Nevada (CCCN) in Las Vegas. He is Associate Chair of the Genitourinary (GU) Committee, and Associate Editor of the Kidney Cancer Journal and Clinical Genitourinary Cancer.

Oncology Consortium | All Rights Reserved 2012-2017
Back to Top